Considering that PDE1A and C are expressed in the RV [116] and that their expression rises in the failing ventricle [5], PDE1 inhibition may promote cardiac effects in the hypertrophied RV of PAH patients. The gene discussed is PDE1A; the disease is pulmonary arterial hypertension.